Healthcare Industry News: MediciNova
News Release - September 8, 2008
MediciNova to Present At Merriman Curhan Ford's 5th Annual Investor Summit 2008SAN DIEGO, Sept. 8, 2008 -- (Healthcare Sales & Marketing Network) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (NasdaqGM:MNOV ) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that Dr. Michael Kalafer, Chief Medical Officer, and Shintaro Asako, Chief Financial Officer, of MediciNova will present a company overview at Merriman Curhan Ford's 5th Annual Investor Summit 2008 on Monday, September 15, 2008, at 11:15 a.m. Pacific time (2:15 p.m. Eastern time). The conference is being held at the Mark Hopkins InterContinental Hotel in San Francisco, California.
A live webcast of the presentation can be accessed through MediciNova's Investor Relations website at http://investors.MediciNova.com. An archived version of the presentation will be available for approximately 60 days following the event.
MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet need with a specific focus on the U.S. market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. MediciNova's pipeline includes six clinical-stage compounds for the treatment of acute exacerbations of asthma, multiple sclerosis, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor and urinary incontinence and two preclinical-stage compounds for the treatment of thrombotic disorders. MediciNova's current strategy is to focus its resources on the development and commercialization of two prioritized assets in its development pipeline: MN-221 for the treatment of acute exacerbations of asthma and MN-166 for the treatment of multiple sclerosis. MediciNova will seek to monetize its other product candidates at key value inflection points. For more information on MediciNova, Inc., please visit http://www.MediciNova.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.